ILCA Annual Conference

Tweets from ILCA

Latest from ILCA

Perioperative Nivolumab/Ipilimumab Combo Showing Early Promising Results in HCC

September 24, 2019

Pathologic complete responses were seen in 29% of patients with resectable hepatocellular carcinoma treated with a perioperative immunotherapy regimen in the first interim analysis of a phase II trial, reported Yehia I. Abugabal, MD, in his presentation at the 2019 ILCA Annual Conference.

Atezolizumab Plus Bevacizumab Offers a Promising Option for Unresectable HCC

September 23, 2019

Clinically meaningful and durable objective responses were observed in the phase Ib subgroup efficacy analysis of atezolizumab plus bevacizumab in patients with previously untreated, unresectable hepatocellular carcinoma.

Real-Life Analysis Confirms Benefit of Sorafenib/Regorafenib Sequence in HCC

September 23, 2019

In an interview with Targeted Oncology, María Varela, MD, PhD, discussed the rationale of the findings from the real-life analysis and their importance for patients with HCC being treated outside of a clinical trial.

Second-Line Pembrolizumab Confers Improved OS, PFS in Patients With Advanced HCC

September 22, 2019

The final analysis of KEYNOTE-240, a phase III study of pembrolizumab in advanced hepatocellular cancer, demonstrated favorable benefit in overall survival and progression-free survival, according to Richard S. Finn, MD, during his presentation at the 13th Annual Conference of the International Liver Cancer Association in Chicago.

Curative and Palliative Treatment Options for Patients With Hepatocellular Carcinoma

September 22, 2019

Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.

RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC

September 22, 2019

Treatment with regorafenib resulted in higher rates of alpha-fetoprotein level response compared with placebo in patients with unresectable hepatocellular carcinoma who had progressed on prior sorafenib, according to an analysis from the phase III RESORCE trial.